Noninvasive Cancer Diagnostics Market

Non-invasive diagnosis is a procedure of identifying a disease without or with minimal incision of the body. These methods involve different techniques such as identifying genetic structure, biomarkers, changes in molecular biology, along with imaging technologies. Cancer is a disease related to genetic alteration of the cells and therefore causing uncontrolled growth and forming tumor like structure. Imaging is the preferred method of cancer detection but cannot have genetic access; on the other hand biopsies which have genetic access are complicated and difficult to perform repetitively during the course of cancer diagnosis and therapy. Therefore newer techniques developed in lines with non invasive diagnosis such as molecular diagnosis, serum based immunoassays and chemical tests to identify chemical components in the body especially from blood and urine. All these procedures are performed either with non-surgical or minimal surgical procedures; therefore these non-invasive cancer diagnostic techniques are becoming more and more popular among healthcare practitioners.

Noninvasive Cancer Diagnostics Market contains market size and forecasts of Noninvasive Cancer Diagnostics in Global, including the following market information:

Global Noninvasive Cancer Diagnostics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Noninvasive Cancer Diagnostics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Clinical Chemistry Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Noninvasive Cancer Diagnostics include Precision Therapeutics, Inc. (U.S.), A&G Pharmaceutical, Inc. (U.S.), Affymetrix Inc. (U.S.), AVIVA Biosciences Corporation (U.S.), BIOVIEW Inc. (U.S.), Laboratory Corporation of America Holdings (LabCorp) (U.S.), Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.), Digene Corporation (U.S.) and Gen-Probe Incorporated (U.S.) and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Noninvasive Cancer Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Noninvasive Cancer Diagnostics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Noninvasive Cancer Diagnostics Market Segment Percentages, by Type, 2021 (%)

Clinical Chemistry

Immunochemistry/Immunoassay

Molecular Diagnostics

Others

Global Noninvasive Cancer Diagnostics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Noninvasive Cancer Diagnostics Market Segment Percentages, by Application, 2021 (%)

Solid Tumors

Blood Cancer

Lung Cancer

Breast Cancer

Others

Global Noninvasive Cancer Diagnostics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Noninvasive Cancer Diagnostics Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Noninvasive Cancer Diagnostics revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Noninvasive Cancer Diagnostics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Precision Therapeutics, Inc. (U.S.)

A&G Pharmaceutical, Inc. (U.S.)

Affymetrix Inc. (U.S.)

AVIVA Biosciences Corporation (U.S.)

BIOVIEW Inc. (U.S.)

Laboratory Corporation of America Holdings (LabCorp) (U.S.)

Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)

Digene Corporation (U.S.)

Gen-Probe Incorporated (U.S.)

IVDiagnostics, Inc. (U.S.)